Seeking Alpha

QualityStocks'  Instablog

QualityStocks
Send Message
QualityStocks (www.qualitystocks.net) assists publicly traded companies by getting their story out to the investment community while helping investors discover emerging companies with plenty of growth potential. Our name, QualityStocks, emphasizes our commitment to connect subscribers with... More
My company:
QualityStocks
My blog:
QualityStocks Micro-Cap and Small-Cap Blog
  • International Stem Cell Corp. (ISCO) Receives Favorable Review In Seeking Alpha Article 0 comments
    Nov 22, 2013 1:53 PM | about stocks: ISCO

    International Stem Cell was recently the topic of a Seeking Alpha article by contributing writer Kingmaker, who outlines the company's stem cell technology, third-quarter financial results, its upcoming investigational new drug (NYSE:IND) filing, and its subsequent market potential.

    To read the full article visit: seekingalpha.com/article/1857401

    International Stem Cell is a biotech company developing new stem cell technology based on a natural process called parthenogenesis, in which stem cells are derived from unfertilized human eggs.

    As the author notes, International Stem Cell's parthenogenesis stem cells "demonstrate superiority" in meeting key criteria in order to be effectual in therapeutic application. With its scientific developments firmly in place, the company is also working to strengthen its financial position.

    "Given that the company appears to be on track with its science, investors are likely wondering if they should invest now. I believe the answer is a resounding yes," the author says.

    International Stem Cell reported record third-quarter revenues of $1.67 million, a year-over-year increase of 41 percent, while cutting general and administrative expenses by approximately 13 percent and ending the quarter with roughly $1.8 million in available cash.

    The article also briefly discusses the company's Parkinson's disease program and its anticipated IND filing with the FDA through a partnership with Duke University. International Stem Cell's aims to develop a product to eliminate Parkinson's disease, which is the second most common neurodegenerative disease affecting 7-10 million people worldwide.

    "As the biotechnology bull market rages on, investors are likely looking for the next niche that can take off. Despite a lot of controversy, I believe that stem cells are that next area to advance medicine to heights never thought possible. International Stem Cell Corporation is quickly gaining recognition with both the medical and investing communities. With several catalysts occurring over the next 12-18 months, investors should get in early before it's too late," Kingmaker states in his conclusion.

    For more information, visit internationalstemcell.com

    QualityStocks provides investor relations services to publicly traded companies in exchange for compensation. This article may be part of our efforts to widen a client's exposure. To read our full disclaimer, visit http://disclaimer.qualitystocks.net

    Stocks: ISCO
Back To QualityStocks' Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.